Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …

In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

Polymyxins are well-established antibiotics that have recently regained significant interest
as a consequence of the increasing incidence of infections due to multidrug-resistant Gram …

Following their initial discovery in the 1940s, polymyxin antibiotics fell into disfavor due to
their potential clinical toxicity, especially nephrotoxicity. However, the dry antibiotic …

Background: Infections caused by multi-drug-resistant Gram-negative bacteria, particularly
Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, that …

The emergence of multidrug-resistant Gram-negative bacteria that cause nosocomial
infections is a growing problem worldwide. Colistin was first introduced in 1952 and was …

Increasing antibiotic resistance in Gram-negative bacteria, particularly in Pseudomonas
aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, presents a global …

Background. Intravenous colistin is difficult to use because plasma concentrations for
antibacterial effect overlap those causing nephrotoxicity, and there is large interpatient …

Acinetobacter baumannii has emerged as a highly troublesome pathogen for many
institutions globally. As a consequence of its immense ability to acquire or upregulate …

In the face of diminishing therapeutic options for the treatment of infections caused by
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …